Borealis is one of the world’s leading providers of advanced and circular polyolefin solutions and a European market leader in base chemicals, fertilizers and the mechanical recycling of plastics. We leverage our polymers expertise and decades of experience to offer value adding, innovative and circular material solutions for key industries. In re-inventing for more sustainable living, we build on our commitment to safety, our people and excellence as we accelerate the transformation to a circular economy and expand our geographical footprint.
With head offices in Vienna, Austria, Borealis employs 6,900 employees and operates in over 120 countries. In 2021, Borealis generated total sales and other income of EUR 10,153 million and a net profit of EUR 1,396 million. OMV, the Austria-based international oil and gas company, owns 75% of Borealis, while the remaining 25% is owned by a holding company of the Abu-Dhabi based Mubadala. We supply services and products to customers around the globe through Borealis and two important joint ventures: Borouge (with the Abu Dhabi National Oil Company, or ADNOC, based in UAE); and Baystar™ (with TotalEnergies, based in the US).
Borealis Healthcare Solutions: The Bormed™ Concept
With over 35 years of experience in the healthcare industry, Borealis Bormed™ is founded on the principles of service, commitment and conformance – Because we care.
Service: Get specialised project support from start to finish, including one-to-one expert consultation and unrivalled access to data that goes beyond product data sheet. By providing global support and thorough market understanding, we help you answer any challenge.
Commitment: Address your sustainability challenges and work towards long term success, with our grades remaining unchanged. While we are committed to the grades as they are, if they require changing, we will provide up to five years´ availability.
Conformance: Conform and adapt to current and future regulatory requirements around the world with Bormed. This safeguards your investment and enables significant cost savings over a project’s lifetime, offering you independent pharmacopeia and ISO10993 analysis reports, and extractable testing data.
Bormed is a trademark of the Borealis Group.
To know more, visit our media gallery or Contact Us.